Vildagliptin and its role in the treatment of diabetes mellitus

Type 2 diabetes mellitus is a most serious medical problem throughout the world. Traditional hypoglycemic agents do not ensure long-term control ofglycemia and fail to affect the natural course of DM. An ideal hypoglycemic medicine must be efficacious, safe, and convenient to use for the preventiono...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Yury Shavkatovich Khalimov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	type 2 diabetes mellitus hypoglycemic therapy incretins dpp-4 inhibitors galvus galvusmet Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/51ddb6efe65e49438e8d82c3da509025
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:51ddb6efe65e49438e8d82c3da509025
record_format	dspace
spelling	oai:doaj.org-article:51ddb6efe65e49438e8d82c3da5090252021-11-14T09:00:15ZVildagliptin and its role in the treatment of diabetes mellitus2072-03512072-037810.14341/2072-0351-5495https://doaj.org/article/51ddb6efe65e49438e8d82c3da5090252010-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5495https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Type 2 diabetes mellitus is a most serious medical problem throughout the world. Traditional hypoglycemic agents do not ensure long-term control ofglycemia and fail to affect the natural course of DM. An ideal hypoglycemic medicine must be efficacious, safe, and convenient to use for the preventionof progressive deterioration of beta-cell function during prolonged therapy; also, it should have positive effect on the outcome of DM. The use of incretinsin the recent decade is a new promising approach to the management of DM2. The group of incretins includes gastrointestinal hormones released inresponse to food intake to stimulate insulin secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of hypoglycemic agents, have been inuse in this country for over 3 years. Vildaglyptin (Galvus) is a representative of DPP-4 inhibitors and GalvusMet is the sole combination of DPP-4inhibitor with metformin registered in Russia. The advent of incretin mimetics necessiatate revision of national and international guidelines for DM2therapy. Results of international clinical studies show that Galvus and GalvusMet are efficacious and safe, they ensure adequate control of glycemiafree from complications and side effects. An important advantage of these preparations is the possibility of their use by elderly patients with arterialhypertension and moderate renal dysfunction and by those at risk of cardiovascular disorders. The evidence-based Galvus information is highly convincing.The advantages of Galvus over traditional agents give reason to recommend it as a medicine of choice for the initiation of DM2 therapy. Approvedcombinations of Galvus with other hypoglycemic agents may be used at all stages of intensive therapy of DM2.Yury Shavkatovich KhalimovEndocrinology Research Centrearticletype 2 diabetes mellitushypoglycemic therapyincretinsdpp-4 inhibitorsgalvusgalvusmetNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 3, Pp 92-96 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus hypoglycemic therapy incretins dpp-4 inhibitors galvus galvusmet Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus hypoglycemic therapy incretins dpp-4 inhibitors galvus galvusmet Nutritional diseases. Deficiency diseases RC620-627 Yury Shavkatovich Khalimov Vildagliptin and its role in the treatment of diabetes mellitus
description	Type 2 diabetes mellitus is a most serious medical problem throughout the world. Traditional hypoglycemic agents do not ensure long-term control ofglycemia and fail to affect the natural course of DM. An ideal hypoglycemic medicine must be efficacious, safe, and convenient to use for the preventionof progressive deterioration of beta-cell function during prolonged therapy; also, it should have positive effect on the outcome of DM. The use of incretinsin the recent decade is a new promising approach to the management of DM2. The group of incretins includes gastrointestinal hormones released inresponse to food intake to stimulate insulin secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of hypoglycemic agents, have been inuse in this country for over 3 years. Vildaglyptin (Galvus) is a representative of DPP-4 inhibitors and GalvusMet is the sole combination of DPP-4inhibitor with metformin registered in Russia. The advent of incretin mimetics necessiatate revision of national and international guidelines for DM2therapy. Results of international clinical studies show that Galvus and GalvusMet are efficacious and safe, they ensure adequate control of glycemiafree from complications and side effects. An important advantage of these preparations is the possibility of their use by elderly patients with arterialhypertension and moderate renal dysfunction and by those at risk of cardiovascular disorders. The evidence-based Galvus information is highly convincing.The advantages of Galvus over traditional agents give reason to recommend it as a medicine of choice for the initiation of DM2 therapy. Approvedcombinations of Galvus with other hypoglycemic agents may be used at all stages of intensive therapy of DM2.
format	article
author	Yury Shavkatovich Khalimov
author_facet	Yury Shavkatovich Khalimov
author_sort	Yury Shavkatovich Khalimov
title	Vildagliptin and its role in the treatment of diabetes mellitus
title_short	Vildagliptin and its role in the treatment of diabetes mellitus
title_full	Vildagliptin and its role in the treatment of diabetes mellitus
title_fullStr	Vildagliptin and its role in the treatment of diabetes mellitus
title_full_unstemmed	Vildagliptin and its role in the treatment of diabetes mellitus
title_sort	vildagliptin and its role in the treatment of diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/51ddb6efe65e49438e8d82c3da509025
work_keys_str_mv	AT yuryshavkatovichkhalimov vildagliptinanditsroleinthetreatmentofdiabetesmellitus
_version_	1718429647863021568

Vildagliptin and its role in the treatment of diabetes mellitus

Ejemplares similares